← Back to Search

Immunomodulator

Topical Imiquimod for Bowen's Disease

Phase 2 & 3

Waitlist Available

Led By Nicole M Owens, MD

Research Sponsored by Brooke Army Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Located on the head and neck, defined as any area superior to the clavicle and anterior to the posterior triangle of the neck

Primary Bowen's disease (first diagnosis)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 14 weeks

Awards & highlights

Study Summary

This trial looks at whether imiquimod can treat Bowens disease of the head and neck better than a placebo. The study found that imiquimod was better at clearing up the disease than the placebo.

Who is the study for?

This trial is for adults with a first-time diagnosis of Bowen's Disease (a type of skin cancer) located on the head or neck. Participants must not have had previous treatments for the lesion, be pregnant, under 18, or have immune system issues like HIV, organ transplants, cancer treatments, or blood cancers.Check my eligibility

What is being tested?

The study tests if Imiquimod cream is better than a placebo at clearing Bowen's Disease after 14 weeks. It's a double-blind trial meaning neither patients nor doctors know who gets real treatment versus placebo to ensure unbiased results.See study design

What are the potential side effects?

Imiquimod may cause local skin reactions such as redness, swelling, itching and burning at the application site. Systemic side effects are rare but can include flu-like symptoms such as fever and fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer is located above my collarbone and in the front part of my neck.

Select...

I have been diagnosed with Bowen's disease for the first time.

Select...

I have been diagnosed with Bowen's disease, a type of skin cancer that hasn't spread beyond the top layer of skin.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 14 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~14 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

histologic clearance of Bowens disease in treated versus placebo group

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Brooke Army Medical CenterLead Sponsor

119 Previous Clinical Trials

26,509 Total Patients Enrolled

Nicole M Owens, MDPrincipal InvestigatorBrooke Army Medical Center Department of Dermatology

Media Library

Imiquimod (Immunomodulator) Clinical Trial Eligibility Overview. Trial Name: NCT00384124 — Phase 2 & 3

Squamous Cell Carcinoma Research Study Groups:

Squamous Cell Carcinoma Clinical Trial 2023: Imiquimod Highlights & Side Effects. Trial Name: NCT00384124 — Phase 2 & 3

Imiquimod (Immunomodulator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00384124 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are volunteers still being accepted for this experiment?

"Unfortunately, this particular trial is not currently recruiting patients. It was initially posted on November 1st 2006 but the most recent update to the listing was on March 25th, 2008. However, there are 54 other trials that potential participants could sign up for."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Topical Imiquimod for Bowen's Disease of the Head and Neck

2006. "Topical Imiquimod for Bowen's Disease of the Head and Neck". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00384124.